Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and Gut
May 18, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, May 18, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief, an educational initiative which aims to...
Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering
April 22, 2021 18:48 ET
|
Impel NeuroPharma
SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize...